Adverse effects cast doubt over Sanofi's Taxotere follow on Jevtana, says NICE
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance declining to recommend Sanofi-Aventis' Jevtana (cabazitaxel) for some prostate cancer patients already treated with the docetaxel (Sanofi's Taxotere). The drug's high cost and concerns about adverse events led the institute to conclude that the drug would not be cost-effective.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.